乳腺癌孤立性腹股沟淋巴结转移的诊治现状

黄海; 周学鲁

doi:10.3877/cma.j.issn.1674-0807.2024.03.008

中华乳腺病杂志(电子版) >

2024 , Vol. 18 >Issue 03: 180 - 183

DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2024.03.008

综述

乳腺癌孤立性腹股沟淋巴结转移的诊治现状

黄海 ,
周学鲁 ^,¹^,^†

展开

^1.523382　东莞，广东医科大学茶山医院普通外科

通信作者：周学鲁，Email：zhouxuelulu@sina.com

收稿日期: 2023-11-11

网络出版日期: 2024-07-03

版权

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计，除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。本刊为电子期刊，以网刊形式出版。

收起

Current status of diagnosis and treatment of isolated inguinal lymph node metastasis in breast cancer

Hai Huang ,
Xuelu Zhou ^,^†

Expand

Received date: 2023-11-11

Online published: 2024-07-03

Copyright

No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.

All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.

Fold

摘要

乳腺癌孤立性腹股沟淋巴结转移是一种较为罕见的恶性转移形式。由于其起病隐匿和缺乏临床特异性表现，这使得其诊断和治疗面临着一定的挑战。本文通过对相关文献的复习，探讨乳腺癌孤立性腹股沟淋巴结转移的流行病学特点、发病率、转移路径与机制、诊断治疗方法以及患者的预后情况。本文为理解乳腺癌孤立性腹股沟淋巴结转移的特点和挑战提供了全面的视角，并为临床医师在诊疗决策中提供了重要的参考信息。

关键词： 乳腺肿瘤; 腹股沟淋巴结; 转移; 治疗

本文引用格式

黄海 , 周学鲁 . 乳腺癌孤立性腹股沟淋巴结转移的诊治现状[J]. 中华乳腺病杂志(电子版), 2024 , 18(03) : 180 -183 . DOI: 10.3877/cma.j.issn.1674-0807.2024.03.008

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

[1]	侯令密，李芳芳，杨宏伟，等. 全乳切除术后放射治疗对T_1～2 N₁ M₀期三阴性乳腺癌预后的价值：一项基于监测、流行病学和最终结果数据库的研究[J/CD]. 中华乳腺病杂志(电子版), 2021, 15(6)：337-345.

[2]	周学鲁，黄海，邓艳庆. 乳腺癌孤立性对侧腹股沟淋巴结转移1例[EB/OL].[2023-05-01].

[3]	Baba M, Tatsuta M, Miya A, et al. A case of breast cancer diagnosed by inguinal lymph node metastasis[J]. Breast Cancer, 2000, 7(2)：173-175.

[4]	Kilçiksiz S, Gökçe T, Kinay M. Isolated inguinal lymph node metastasis from breast carcinoma-case report and review of the literature[J]. J BUON, 2006, 11(2)：229-232.

[5]	Jebbin NJ, Adotey JM. Metastatic carcinoma of the breast with inguinal lymph node involvement: a report of two cases[J]. Niger J Clin Pract, 2008, 11(4)：383-385.

[6]	Goyal S, Puri T, Julka PK. Breast cancer with inguinal node recurrence[J]. J Egypt Natl Canc Inst, 2015, 27(1)：41-43.

[7]	Ganesh YP, Arulappan T, Sivaraja, et al. A rare case of isolated inguinal lymphnode metastasis from breast carcinoma - case report[J]. J Med Sci Clin Res, 2019, 7(1)：1167-1170.

[8]	Kimoto T, Kohno N, Okamoto A, et al. A case of contralateral inguinal lymph node metastases from breast cancer[J]. Surg Case Rep, 2021, 7(1)：99.

[9]	Das Majumdar SK, Muraleedharan A, Mahapatra BR, et al. Inguinal lymph node metastasis in treated breast cancer: an extremely rare presentation and review of literature[J]. BMJ Case Rep, 2022，15(6): e249152.

[10]	赵红梅，侯宽永，柳剑英. 乳腺癌淋巴系统腹股沟的特殊转移(附1例报告) [J]. 中国微创外科杂志，2004, 4(4)：2.

[11]	李倩，李俏，徐兵河，等. 17例乳腺癌腹股沟淋巴结转移患者的临床特征和预后分析[J]. 中华肿瘤杂志，2013, 35(3)：207-211.

[12]	Guerry RL, Pratt-Thomas HR. Carcinoma of supernumerary breast of vulva with bilateral mammary cancer[J]. Cancer, 1976, 38：2570-2574.

[13]	McMaster J, Dua A, Dowdy SC. Primary breast adenocarcinoma in ectopic breast tissue in the ulva[J]. Case Rep Obstet Gynecol, 2013, 2013：721 696.

[14]	周璐，徐静，徐琰. 循环肿瘤DNA检测在乳腺癌中的临床应用[J/CD]. 中华乳腺病杂志(电子版), 2022, 16(1)：47-50.

[15]	Liu B, Hu Z, Ran J, et al. The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: novel prognostic indexes based on ctDNA[J]. Breast, 2022，65：116-123.

[16]	Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence[J]. Clin Cancer Res, 2019, 15；25(14)：4255-4263.

[17]	Sant M, Bernat-Peguera A, Felip E, et al. Role of ctDNA in breast cancer[J]. Cancers (Basel), 2022, 14(2)：310.

[18]	Hellman S, Weichselbaum RR. Oligometastases[J]. J Clin Oncol, 1995, 13(1): 8-10.

[19]	Katipally RR, Pitroda SP, Juloori A, et al. The oligometastatic spectrum in the era of improved detection and modern systemic therapy[J]. Nat Rev Clin Oncol, 2022, 19(9): 585-599.

[20]	欧丹，许赪，陈佳艺. Ⅳ期乳腺癌寡转移局部治疗进展[J]. 外科理论与实践，2018, 23(5)：469-471.

[21]	Choi SH, Kim JW, Choi J, et al. Locoregional treatment of the primary tumor in patients with de novo stage Ⅳ breast cancer: a radiation oncologist’s perspective[J]. Clin Brast Cancer, 2017, 18(2)：e167-e178.

[22]	Harris E, Barry M, Kell MR. Meta-analysis of determine if surgical resection of the primary tumor in the setting of stage Ⅳ breast cancer impacts on survival[J]. Ann Surg Oncol, 2013, 20(9)：2828-2834.

[23]	Lu S, Wu J, Fang Y, et al. The impact of surgical excision of the primary tumor in Ⅳ breast cancer on survival: a meta-analysis[J]. Oncotarget, 2018, 9(14)：11 816-11 823.

[24]	中国临床肿瘤学会指南工作委员会．中国临床肿瘤学会(CSCO)乳腺癌诊治指南[M]. 北京：人民卫生出版社，2021：76-98.

[25]	Wynn CS, Tang SC. Anti-Her-2 therapy in metastatic breast cancer: many choices and future directions[J]. Cancer Metastasis Rev, 2022, 41(1)：193-209.

[26]	李芷君，徐兵河. 中国乳腺癌临床研究进展[J/CD]. 中华乳腺病杂志(电子版), 2022, 16(1)：1-5.

[27]	王淑伟，殷进军，邵姜超，等. 放射治疗对乳腺癌寡转移局部控制的影响[J/CD]. 中华乳腺病杂志(电子版), 2023, 17(2)：72-79.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

参考文献